Resource Summary Report

Generated by dkNET on Aug 8, 2026

PerCP anti-human CD3

RRID:AB_893298
Type: Antibody

Proper Citation

BioLegend Cat# 300428, RRID:AB_893298

Antibody Information

URL: http://antibodyregistry.org/AB_893298

Proper Citation: BioLegend Cat# 300428, RRID:AB_893298

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone UCHT1

Antibody ID: AB_893298

Vendor: BioLegend

Catalog Number: 300428

Alternative Catalog Numbers: 300427

Record Creation Time: 20250819T235649+0000

Record Last Update: 20250820T065428+0000

Ratings and Alerts

No rating or validation information has been found for PerCP anti-human CD3.

No alerts have been found for PerCP anti-human CD3.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Reilly RB, et al. (2024) An altered natural killer cell immunophenotype characterizes clinically severe pediatric RSV infection. Science translational medicine, 16(768), eado6606.

Reincke SM, et al. (2023) Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells. Cell, 186(23), 5084.

Tamura T, et al. (2023) Single-cell transcriptomics reveal a hyperacute cytokine and immune checkpoint axis after cardiac arrest in patients with poor neurological outcome. Med (New York, N.Y.), 4(7), 432.

Preechanukul A, et al. (2023) Identification and function of a novel human memory-like NK cell population expressing CD160 in melioidosis. iScience, 26(8), 107234.

Moore SC, et al. (2023) Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens. Med (New York, N.Y.), 4(3), 191.

Tan ZC, et al. (2023) Mixed IgG Fc immune complexes exhibit blended binding profiles and refine FcR affinity estimates. Cell reports, 42(7), 112734.

Wenthe J, et al. (2023) Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models. Journal of translational medicine, 21(1), 506.

Terahara K, et al. (2022) SARS-CoV-2-specific CD4+ T cell longevity correlates with Th17-like phenotype. iScience, 25(9), 104959.

Jaiswal A, et al. (2022) An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes. Cancer cell, 40(5), 524.

Wenthe J, et al. (2021) Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy. Cancer immunology, immunotherapy : CII, 70(10), 2851.

Leng T, et al. (2019) TCR and Inflammatory Signals Tune Human MAIT Cells to Exert Specific Tissue Repair and Effector Functions. Cell reports, 28(12), 3077.

Ahmed R, et al. (2019) A Public BCR Present in a Unique Dual-Receptor-Expressing Lymphocyte from Type 1 Diabetes Patients Encodes a Potent T Cell Autoantigen. Cell, 177(6), 1583.

Wang W, et al. (2019) Type I Interferon Therapy Limits CNS Autoimmunity by Inhibiting CXCR3-Mediated Trafficking of Pathogenic Effector T Cells. Cell reports, 28(2), 486.